Kornimate/medical-research-clean huggingface dataset:
observational study of thrombogenic properties in 220 patients with proximal femur fracture

Conditions: Thromboembolism

Summary: measurement of thrombogenic properties by teg and mea and observation of thrombotic events over 2 years in 220 patients with hip fracture.

patients with proximal femur fracture have high incidences of thrombotic events. by the two "bed-side" methods teg (thrombelastography) and mea (multiple electrode aggregometry), the thrombogenic properties of 220 patients with proximal femur fracture will be measured at time of hospital admission and 4 times over a period of 6 months postoperatively, and the patients will be followed in a total length of 2 years to register thrombotic events.

Eligibility criteria:
inclusion criteria: * patients older than 18 years who are admitted to our hospital for orthopedic surgery of proximal femur fracture. * the study participants must be capable to sign/accept informed concent exclusion criteria: * patients with severe dementia or that of other causes not ar capable to give informed concent. * patients with known or suspected cancer, blood diseases or bleeding disorders * surgery last 6 months * severe renal- (egfr (creatinine) \<30) * severe hepatic failure (2x unl for bilirubin, 3x unl for alat or inr \> 1,3 without anticoagulation treatment) * patients that, by drug spesification or -spc, not are eligible for postoperative thrombosis prophylaxis

Keywords: teg mea thrombotic events vte lmwh hip fractures
semaglutide versus glp-1 receptor agonists. effectiveness , safety and quality of life in patients with diabetes mellitus 2. observational, prospective and multicenter study. several study.

Conditions: Weight Loss; Diabetes Mellitus, Type 2; Quality of Life; Safety Issues

Summary: introduction: glp-1 receptor agonists (aglp1) act increasing pancreatic insulin secretion in response to the glucose, they reduce glucagon secretion and reduce appetite by acting in the central level. several aglp1 were approved through different clinical trials where they showed efficacy in the glycemic control and reduction in cardiovascular events. they also showed weight loss in different clinical trials with patients with diabetes mellitus 2 (dm2) and also in specific clinical trial where the weight loss was the primary endpoint (step study). objective: the objective is to evaluate and compare the weight loss in patients with dm2 treated with the different aglp1 for the first time. secondary endpoints are hba1c reduction, changes in quality of life and physical activity and the safety of these drugs. design: it is a postauthorization, multicenter, non-randomized and prospective study. patients that will start treatment for the first time with aglp1 will be recruited in 10 primary care centers in sergas galician hospitals for a period of 6 months and 44 weeks of follow-up. the primary endpoint will be to evaluate the wight loss with the different aglp1 and the secondary endpoint will be hba1c reduction, changes in the quality of life through the euroqol-5d and changes physical activity through the sf-12 questionnaire, and also the safety of these drugs. the sample size will be of 360 patients. statistical analysis: previous studies showed efficacy in weight loss with semaglutide about (3,6-4,9 kg), while with other aglp1 the weight loss was smaller , about (0,86-2,96 kg). based in these data and with a 5% of significance level, a weight loss average in the aglp1 group of 2,5 kg, average in semaglutide group of 4,2 kg, and combination deviation of 3,0kg, including 360 subjects we will have a statistical power above 90% to detect differences through t-test for independent samples. the justification of this simple size was performed with the statistical software spss 3.0 conclusions: the several study will try to provide information about weight loss efficacy, changes in quality of life, physical activity and safety of the aglp1in patients with dm2 that start treatment with these drugs in the real life (real-world evidence)


Eligibility criteria:
inclusion criteria: * patients 18 years old or over * to start with the first funded dose of glp1 receptor agonists ( bmi \> 30kg/m2) * treated with another oral antidiabetic exclusion criteria: * diagnosis of diabetic retinopahty and family history of thyroid cancer

Keywords: semaglutide glp1 receptor agonists diabetes mellitus 2 weight loss bmi
exercise and tumor blood flow in breast cancer patients

Conditions: Cancer, Breast

Summary: this research aims at investigating tumor blood flow response to acute exercise in human cancer patients. it is hypothesized and expected that acute exercise increases tumor blood flow, which could plausibly increase the efficacy of cancer treatment.

physical activity has been applied as an adjunctive therapy in the secondary prevention of many cancers, but very little is currently known clinically and mechanistically about the effects of physical activity and exercise on tumor itself. based on recent evidence from pre-clinical studies, it is plausible to expect that changes in tumor blood flow and its heterogeneity, oxygenation, and metabolism due to exercise would increase the delivery of chemotherapy and other cancer drugs into the tumor increasing the efficacy of cancer treatment. twenty (20) newly diagnosed breast cancer patients will be recruited to investigate whether these pre-clinical findings can be extended to humans to serve as an evidence-based proof-of-concept for the possible inclusion of exercise in the treatment of cancer during chemotherapy. to study the effect of acute physical exercise on tumor blood flow and its heterogeneity, supine bicycle exercise in a positron emission tomography (pet) scanner will be used to exercise breast cancer patients. these experiments are additional measurements to their normal treatments, and no new interventional approaches will be conducted in this study. the study consists of one fitness test assessment, and tumor blood flow measurements with pet at rest and during supine cycling exercise.

Eligibility criteria:
inclusion criteria: * newly diagnosed breast cancer exclusion criteria: * abnormal fatigue, anemia, or physical dysfunction due to the disease
safety, effectiveness and participant satisfaction study of a dermal filler (of radiesse® (+) lidocaine) in the treatment of ageing signs in the face

Conditions: Signs of Facial Aging With Volume Loss in the Upper Cheeks, Nasolabial Folds and Marionette Lines

Summary: the primary objective is to collect clinical data to confirm performance and safety for radiesse® (+) lidocaine, when used in accordance with its labelling in the treatment of nasolabial folds, marionette lines and/or upper cheek volume loss.


Eligibility criteria:
inclusion criteria: 1. male or female greater than or equal to (\>=) 18 years old. 2. participants seeking for dermal filler/volumising treatment in at least two of the following indications: * nasolabial folds; * marionette lines; * cheek volume loss. 3. nasolabial folds volume deficit of moderate to very severe intensity (grade 2 to 4) on the merz nasolabial folds scale with symmetrical rating at day 1 as determined by the blinded rater and confirmed by the treating investigator afterwards. 4. marionette lines volume deficit of moderate to very severe intensity (grade 2 to 4) on the merz marionette lines scale with symmetrical rating at day 1 as determined by the blinded rater and confirmed by the treating investigator afterwards. 5. upper cheek volume deficit of moderate to very severe intensity (grade 2 to 4) on the merz upper cheek fullness scale with symmetrical rating at day 1 as determined by the blinded rater and confirmed by the treating investigator afterwards. at least two of the inclusion criteria 3, 4, and 5 must be fulfilled. depending on the fulfilled criteria, the respective indications will be treated. exclusion criteria: 1. any prior treatment with silicone, polymethyl methacrylate, fat injections, poly l-lactic acid or permanent dermal fillers in the face. 2. any prior facial surgery, including facial plastic surgery, thread lift, any unknown treatment, or any surgical permanent implant that could interfere with performance assessments. 3. prior treatment within the past 24 months with porcine based collagen fillers or with volumisers (e.g., belotero® volume or others) in the area to be treated. 4. prior treatment within the past 18 months with calcium hydroxylapatite in the area to be treated. 5. prior treatment within the past 12 months with hyaluronic acid in the area to be treated. 6. prior treatment within the past 6 months with facial dermal therapies (e.g. epilation, ultraviolet irradiation, radiofrequency, facial ablative or non-ablative laser treatment, microderm abrasion, mechanical or chemical peels, non-invasive skin-tightening \[e.g., ultherapy, thermage\] or surgical procedures) or plans to receive this during participation in the study.
observational non-interventional study (anwendungsbeobachtung) with telmisartan in high-risk hypertensives

Conditions: Hypertension; Obesity

Summary: this observational non-interventional study will assess (under conditions of clinical practice in daily routine) the antihypertensive efficacy of telmisartan treatment with or without active promotion of lifestyle changes in hypertensive patients at high cardiovascular risk

study design:

Eligibility criteria:
inclusion criteria: patients with essential hypertension aged \>/= 18 years with one of the following risk factors: history of coronary artery disease or stroke/tia or peripheral artery disease or diabetes mellitus. exclusion criteria: according to spc
an evaluation of sprayshield in reducing post-operative adhesion formation following major open abdominal surgery

Conditions: Ulcerative Colitis; Familial Polyposis

Summary: this will be a prospective, multi-center, randomized, single blind study to collect and evaluate post-market clinical data on the sprayshield adhesion barrier system as an adjuvant to good surgical technique for the reduction of postoperative adhesion formation following major open abdominal surgery.


Eligibility criteria:
inclusion criteria: * diagnosis of ulcerative colitis or familial polyposis and require two-stage surgery for treatment of either of these disorders will be eligible
volatolomic and proteomic profile for early diagnosis of lung cancer

Conditions: Lung Cancer; Non-small Cell Lung Cancer Stage I; Non-small Cell Lung Cancer Stage II; Lung Cancer Diagnosis

Summary: the goal of this prospective, case-control study is to discover the specific "omics" biomarkers of early stage of lung cancer using the non-invasive samples (breath, urine and serum) in a total of 200 subjects (100 healthy controls and 100 lung cancer patient). the main questions it aims to answer are: * which are the "omics" biomarkers that characterize the early stage of lung cancer? * how to translate laboratory data into clinical data? for each participant we will collected the breath, urine and blood samples. in lung cancer patients group the samples will be sample before lung cancer resection. the samples of breath, urine and serum will be analysed using different type of analysis: enose and the gas chromatography combined with ion mass spectrometry (gc/ims). moreover, serum will be analyzed by mass-spectrometry-based proteomics. the purpose of these analyses will be to find biomarkers capable of distinguishing the early-stage of lung cancer from the healthy group. followup will be performed to evaluate the possible change of the volatolomic and proteomic profile.

all partecipants will sign the informed consent before the sampling procedures. in addition, they will complete the clinical questionnaire containing medical history, smoking history and psychological evaluation.we will conduct the trial according to the ich good clinical practice (gcp) guidelines. keeping accurate and consistent records is essential to a cooperative study.the ieo data management office will responsible of the study database and data management.

Eligibility criteria:
inclusion criteria: 1. lung cancer group * diagnosis of early stage - lung cancer * signed informed consent * completed questionnaire 2. healthy subjects * high risk individuals (heavy smokers, subjects with pulmonary disease non-cancer related or with a familiar history of lung cancer disease) * recent (within 6 months) negative chest x-ray or ct scan exclusion criteria: both groups * no previous chemo or radiotherapy for lung cancer * no previous malignancies within last 5 years * no abuse of alcohol (no more than 1 litre of wine for day). * no patients with psychiatric, addictive, or any disorder, which compromises ability to give informed consent for participation in this study

Keywords: lung cancer early diagnosis biomarkers proteomic volatomic
cervical dizziness in patients with acute non-specific neck pain

Conditions: Dizziness; Neck Pain; Elastography

Summary: acute non-specific neck pain (ansnp) is one of the causes of cervicogenic dizziness (cd).to investigate the severity of cd in patients with ansnp and to determine the efficacy of the treatment and follow-up.

the primary aim of this study was to investigate the contribution of cervical proprioception impairment to the development of cervical dızzıness in patients with acute non specific neck pain and to determine the efficacy of the treatment and follow-up performed in patients coexisting with cervical dizziness and nonspecific neck pain. our hypothesis was that the objective measurement of muscle stiffness with shear-wave elastography could aid in the differential diagnosis in patients coexisting with cervical dizziness and non specific neck pain.

Eligibility criteria:
inclusion criteria: * inclusion criteria were as follows: pain on palpation in the neck area, neck stiffness, tension and tenderness in the neck muscles, and cervical movement limitation. all the patients included in the study had no history of a maneuver for dizziness, no history of ototoxic drug use, and had normal hearing. exclusion criteria: * exclusion criteria included presence of benign paroxysmal positional vertigo (bppv), meniere's disease, migraine-associated vertigo, vertebrobasilar insufficiency, postural hypotension, a history of trauma to the cervical region, myofascial pain syndrome, and neurological, rheumatological, and systemic diseases. additionally, patients detected with neck-related conditions (cervical spondylosis, cervical disc hernia, fracture, dislocation, spondylolisthesis, scoliosis) and fibromyalgia in cervical magnetic resonance imaging (mri) were also excluded from the study.

Keywords: elastography neck pain cervical dizziness
non-invasive brain stimulation as an innovative treatment for chronic neglect patients

Conditions: Spatial Neglect

Summary: background stroke is a leading cause of neurological impairments in language, motor and cognitive functions. next to traditional stroke treatment, non-invasive brain stimulation (nibs) offers the potential to facilitate stroke recovery as a complementary approach. here, we aim at exploiting the principles of nibs, specifically transcranial alternating current stimulation (tacs), to promote functional recovery of people with neglect symptoms following stroke. objective to determine whether neglect training complemented with tacs treatment in chronic stroke patients suffering from neglect improves neglect-related symptoms compared to neglect training with sham stimulation. study design double-blind randomized placebo-controlled intervention study. after enrollment and completion of baseline measurements, participants are randomly assigned to either the active tacs group or sham (control) group. intervention we will combine an evidence based visual scanning training (vst) with 40 minutes of (active or sham) tacs at alpha frequency. the intervention is administered three times a week for a duration of six weeks. outcomes of the study performance on standard, conventional neuropsychological tests, as well as on adl observation scales.


Eligibility criteria:
inclusion criteria: * neurologically objectified stroke; * stroke occurred when patient was 18-80 years of age; * chronic stroke (\>6 months post-stroke onset); * sufficient comprehension and communication skills to benefit from training (based on clinical judgement); and * a screening containing four neuropsychological tests will be performed to evaluate the current severity of the neglect, since the diagnosis of neglect may have been established months or even years ago in our sample of chronic stroke patients. exclusion criteria: * currently engaging in cognitive rehabilitation treatment or neglect treatment; * physically or mentally unable to participate (based on clinical judgment); * hemianopsia (based on clinical judgement); * severe communicative disability, as task descriptions need to be understood; * local scalp injuries\*; * eczema on scalp or psoriasis\*; * diagnosed (neuro)psychiatric or neurodegenerative diseases\*; * current alcohol and/or drug abuse\*; and * pregnancy\*. * due to tacs safety considerations.
port size and post-operative pain perception by patients

Conditions: Pain

Summary: the purpose of this study is to determine if there is a difference in pain perception by participants when the assistant port size varies by 50% (8 mm to 12 mm).

minimally invasive approaches trade a single longer incision for 4-5 smaller incisions that allow abdominal access and abdominal insufflation through "ports". the increase in operative times is mostly due to the need to pass suture, needles, cameras and instruments through the abdominal ports. while, it is intuitive that smaller abdominal ports will result in less pain at the incision site, the port size is also limited by instrument size and the size of the needle. when ports are smaller, it can take a little more time for a needle or instrument to be passed into the port. there is a paucity of research comparing different port sizes as they relate to participate pain and operative time especially in a randomized controlled trial setting. the investigators goal would be to determine if there is a difference in pain perception by patients when the assistant port size varies by 50% (8 mm to 12 mm).

Eligibility criteria:
inclusion criteria: * laparoscopic surgery for pelvic organ prolapse. * proficiency in english . exclusion criteria: * not proficiency in english * previous participation/randomization in the study at a previous visit * pregnant women cannot participate * history of abdominal wall pain * chronic pain patients
safety and dose finding study of xigris in hemodialysis patients

Conditions: End Stage Renal Disease

Summary: the purpose of the study is to assess the safety of xigris (drotrecogin alfa) as an anticoagulant at different dose levels during dialysis treatment in patients with end stage renal disease (esrd).

in united states, there are over 300,000 patients with esrd who require hemodialysis. clinical hemodialysis takes place three times a week and is dependent on adequate anticoagulation throughout the three to four hour procedure. infection is one of the most common causes of death for patients with esrd treated with hemodialysis (25%). xigris (drotrecogin alfa activated) is a recombinant form of human activated protein c and is successfully used for treatment of adult patients with severe sepsis. in addition to its fibrinolytic properties, drotrecogin alpha has both an anti-inflammatory effect, and an anti-coagulant effect. however, there are few safety and no efficacy data on the effect of xigris in esrd patients as an anticoagulant.

Eligibility criteria:
inclusion criteria: 1. \>18 2. usually used heparin with hd exclusion criteria: 1. plt \<100 2. pregnancy 3. h/o bleeding diathesis 4. h/o cva 5. pt on ticlid/plavix/warfarin 6. sbp \>200 7. baseline ptt\>50 8. inr\>1.6

Keywords: hemodialysis anticoagulation xigris ptt
seroprevalence of sars cov 2 antibodies in previously undiagnosed healthcare workers

Conditions: SARS-CoV 2; COVID-19

Summary: the purpose of this study is to identify healthcare workers with sars cov 2 antibodies who have not been previously diagnosed and are presumed covid-19 negative, then determine the level of immunity in this population which could inform further decisions about widespread antibody testing in a healthcare worker population.

enrolled participants will complete a survey gauging their level of confidence they will be antibody positive. participants will then complete serologic testing for sars cov 2 igg antibodies. the study will characterize the prevalence of antibody positivity in this population and assess whether there is a correlation between a pre-test confidence level using a likert scale and actual antibody positivity.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years old. * mayo clinic employee in procedural and surgical area. * suspected covid-19 exposure. * completed pcr test twice with negative results. exclusion criteria: - refusal to participate in this study.
autologous bone marrow mesenchymal stem cells transplantation via hepatic artery in patients with liver cirrhosis

Conditions: Liver Cirrhosis

Summary: the purpose of this study is to investigate the efficacy of autologous bone marrow mesenchymal stem cells (mscs) transplantation via hepatic artery in the treatment of liver cirrhosis. liver function was monitored by serum examination. the levels of serum alanine aminotransferase (alt), total bilirubin (tb), prothrombin time (pt) and albumin (alb) were examined at pre-transplantation, and 3 days to 2 years post-transplantation. child-pugh scores and clinical symptoms were also observed simultaneously.

patients with liver cirrhosis were randomly separated into two groups. autologous mscs were infused to patients using interventional method via hepatic artery for one group. the catheter was inserted to proper hepatic artery. after the catheter placed at proper hepatic artery was confirmed by angiography, autologous bone marrow mscs were infused slowly for 20-30 minutes. the control group accepted conserved therapy.

Eligibility criteria:
inclusion criteria: * age 18-70 years. * imaging evidences of liver cirrhosis. * child-plough score of 10 or more. exclusion criteria: * liver tumor on ultrasonography, ct or mri examination. * problems in organs other than the liver(e.g.the heart or lungs). * history of moderate to severe hepatic encephalopathy or variceal bleeding. * imaging evidences of vascular thromboses. * coma.

Keywords: stem cells liver cirrhosis radiology interventional transplantation